Please ensure Javascript is enabled for purposes of website accessibility

MediPharm Labs Scores Cannabis Oil Supply Deal in Australia

By Eric Volkman - Mar 18, 2020 at 9:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company didn't provide the financial details of the arrangement, however.

MediPharm Labs (MEDIF 2.14%) has nabbed a customer Down Under. The company announced Wednesday that its Australian subsidiary signed an agreement with privately held Compass Clinics for the supply of cannabis oil products. This is a white label arrangement, in which Compass Clinics will use MediPharm's supplies to create its own branded line of products.

MediPharm didn't reveal the terms or the price of the deal.

The news comes less than two months after MediPharm announced it secured a license from the Australian government to import cannabis and related substances from its native Canada. 

A jar of cannabis oil.

Image source: Getty Images.

Australia legalized medical cannabis in 2016, and the numbers of both patients and prescriptions has risen substantially. According to MediPharm Labs, as of the end of February the Australian Therapuetic Goods Administration (TGA) -- the national regulator of pharmaceuticals -- green-lighted over 34,500 prescriptions for product.

The country is tightening its oversight of the medical marijuana shipped into the country, on the back of that increased demand. Earlier this month, TGA announced it planned to increase the number of quality audits of medical cannabis. MediPharm has an advantage in this regard, as the marijuana company has secured crucial good manufacturing practices (GMP) certification for its wares sold in the country.

In the press release heralding the Compass Clinics deal, MediPharm said its supplies "will help Compass better serve its existing patient base and continue to expand its presence in one of the fastest growing medical cannabis markets in the world."

On Wednesday, however, MediPharm's stock experienced a slightly deeper decline than the S&P 500 index on the day, falling by over 7%. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MediPharm Labs Corp. Stock Quote
MediPharm Labs Corp.
$0.07 (2.14%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.